国家: 马来西亚
语言: 英文
来源: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Tafamidis
PFIZER (MALAYSIA) SDN. BHD.
Tafamidis
30 Capsules
Catalent Pharma Solutions, LLC
Not Applicable. 阅读完整的文件
1 1. NAME OF THE MEDICINAL PRODUCT Vyndamax ® 61 mg soft capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each soft capsule contains 61 mg of micronized tafamidis. Excipient with known effect Each soft capsule contains no more than 44 mg of sorbitol (E 420). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Soft capsule. Reddish brown, opaque, oblong (approximately 21 mm) capsule printed with “VYN 61” in white. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Vyndamax is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated under the supervision of a physician knowledgeable in the management of patients with amyloidosis or cardiomyopathy. When there is a suspicion in patients presenting with specific medical history or signs of heart failure or cardiomyopathy, etiologic diagnosis must be done by a physician knowledgeable in the management of amyloidosis or cardiomyopathy to confirm ATTR-CM and exclude AL amyloidosis before starting tafamidis, using appropriate assessment tools such as: bone scintigraphy and blood/urine assessment, and/or histological assessment by biopsy, and transthyretin (TTR) genotyping to characterise as wild-type or hereditary. Posology The recommended dose is one capsule of Vyndamax 61 mg (tafamidis) orally once daily (see section 5.1). Vyndamax should be started as early as possible in the disease course when the clinical benefit on disease progression could be more evident. Conversely, when amyloid-related cardiac damage is more advanced, such as in NYHA Class III, the decision to start or maintain treatment should be taken at the discretion of a physician knowledgeable in the management of patients with amyloidosis or cardiomyopathy (see section 5.1). There are limited clinical data in patients with NYHA Class IV. 2 If vomiting occurs after dosing, and the intact Vyndamax capsule is identified, then an addit 阅读完整的文件